





Does drug consumption has an influence on plasmids diffusion in CZA-resistant *Klebsiella pneumoniae* isolates?

Federica Sacco¹, Luisa Torrini², Fabiana Diaco², Agnese Viscido¹, Guido Antonelli^{1,2}, Giammarco Raponi^{1,3}

¹Clinical Microbiology Laboratory, University Hospital Policlinico Umberto I of Rome (Italy), ²Department of Molecular Medicine, Sapienza University of Rome (Italy), ³Department of Public Health and Infectious Disease, Sapienza University of Rome (Italy)

Introduction

Carbapenem-resistant *Klebsiella pneumoniae* strains emerged as an important cause of health care-associated infections in the last decade. Ceftazidime/avibactam (CZA) was introduced in Italy for the treatment of multi-drug-resistant gram-negative bacteria since 2018, and isolation of CZA-resistant strains of K. pneumoniae has been observed. Based on data on CZA consumption, the aim of this study was to analyze whether CZA-resistance could be related to the circulation of bla_{KPC} in plasmids from 2019 to 2021 in a tertiary care University Hospital.

Material and methods

CZA-resistant *K. pneumoniae* were isolated in 2019-2021 from patients admitted to the Policlinico Umberto I of Rome (Italy). The strains (n=37) were analyzed with RT-PCR (GeneXpert, Cepheid, USA), MLST and WGS (Illumina and Nanopore Technologies). CZA consumption was expressed in DDD/1000 admission.


Results

28 $bla_{\rm KPC}$, with different variants, and 9 $bla_{\rm NDM}$ genes were detected in CZA-resistant K. pneumoniae isolates (Table 1.). The CZA-resistant strains belonged to different Sequence Type: ST512, ST307, ST101, ST111, ST15, ST37 (Figure 1). They acquired $bla_{\rm KPC}$ via identical pKpQIL plasmids, with a huge variability between the Klebsiella genome. In ST512 and ST111, pKpQIL was the most common plasmid; in ST307, $bla_{\rm KPC}$ was located on the pKpQIL-pKPN plasmid fusion; in ST101 a portion of the pKpQIL plasmid was transferred on plasmids carrying the FIA(HI1)-R replicons; in ST37 $bla_{\rm KPC}$ were detected on pKpQIL and pKpN (1); in ST15 $bla_{\rm NDM}$ were identified on IncC plasmid (2). Several strains showed increased plasmid copy number and amplification of $bla_{\rm KPC}$ copies. The CZA consumption expressed in DDD/1000 admissions was constantly increasing, with values ranging from 198.1 to 323.5 DDD*1000 admissions, in the period 2018-2021 (Figure 2). Since 2018, there has been a positive trend in CZA consumption.

Table 1. CZA-resistant K. pneumoniae strains.

| Strain | Ward | ST | KPC | Year | Sample | MIC CZA | Plasmid | WGS |
|--------|------|-----|---------|------|--------|---------|-------------------------------|-----|
| | | | variant | | | (mg/L) | (copy number per cell) | |
| 2 | ICU | 512 | KPC-67 | 2019 | BC | 48 | pKpQIL | Yes |
| 4 | ICU | 512 | KPC-49 | 2019 | BC | 12 | pKpQIL (0.47x) | Yes |
| 5 | ICU | 512 | KPC-66 | 2019 | BC | 12 | pKpQIL | Yes |
| 6 | ICU | 512 | KPC-29 | 2019 | BC | 24 | pKpQIL (0.73x) | Yes |
| 7 | ICU | 512 | KPC-3 | 2019 | BC | 12 | pKpQIL(0.58x)+CoIRNAI (1.62x) | Yes |
| 8 | ICU | 512 | KPC-67 | 2019 | BC | 24 | pKpQIL | |
| 9 | ICU | 512 | KPC-31 | 2019 | BC | 32 | pKpQIL | Yes |
| 10 | ICU | 101 | KPC-68 | 2019 | BC | 32 | FIIk-FIA(HI1)-R | Yes |
| 11 | ICU | 512 | KPC-67 | 2019 | BC | 16 | pKpQIL | |
| 13 | ICU | 512 | KPC-67 | 2019 | UR | 32 | pKpQIL | |
| 14 | MED | 307 | KPC-31 | 2019 | RS | 12 | pKpQIL -pKPN | |
| 16 | ICU | 101 | KPC-39 | 2019 | BC | 24 | FIIk-FIA(HI1)-R | Yes |
| 17 | MED | 307 | KPC-31 | 2019 | BC | 12 | pKpQIL | Yes |
| 18 | SU | 512 | KPC-67 | 2019 | UR | 24 | pKpQIL | |
| 19 | SU | 101 | KPC-66 | 2019 | AF | 12 | FIIK-R + chromosome | Yes |
| 20 | ICU | 512 | KPC-67 | 2019 | BC | 12 | pKpQIL (0.7x) | Yes |
| 21 | MED | 101 | KPC-31 | 2019 | UR | >256 | FIIk-FIA(HI1)-R +CoIRNAI | Yes |
| 23 | HEM | 307 | KPC-31 | 2019 | RS | 12 | pKpQIL -pKPN (1.71x) | Yes |
| 24 | HEM | 512 | KPC-66 | 2019 | RS | 12 | pKpQIL (0.67x) | Yes |
| 26 | HEM | 307 | KPC-31 | 2019 | RS | 12 | pKpQIL -pKPN | |
| 27 | ICU | 512 | KPC-67 | 2019 | UR | 24 | pKpQIL | |
| 29 | ICU | 512 | KPC-67 | 2019 | RS | 24 | pKpQIL | |
| 30 | HEM | 307 | KPC-31 | 2020 | UR | 12 | pKpQIL -pKPN | |
| 31 | ICU | 101 | KPC-68 | 2020 | BC | 32 | FIIk-FIA(HI1)-R | Yes |
| 20-2 | ICU | 512 | KPC-67 | 2020 | UR | 24 | pKpQIL -pKPN (1.74x) | Yes |
| 32 | MED | 512 | KPC-70 | 2020 | RTS | >256 | pKpQIL (0.67x) | Yes |
| 34 | MED | 111 | KPC-69 | 2020 | RS | 8 | pKpQIL (0.68x) | Yes |
| 24-2 | ICU | 512 | KPC-67 | 2020 | WS | 16 | pKpQIL (0.45x) | Yes |
| 831 | ICU | 15 | NDM-1 | 2020 | RTS | >256 | IncC | Yes |
| 8471 | PNE | 15 | NDM-1 | 2020 | RS | >256 | IncC | |
| 917 | ICU | 15 | NDM-1 | 2020 | RS | >256 | IncC | |
| 921 | ICU | 15 | NDM-1 | 2020 | RS | >256 | IncC | |
| 1017 | PNE | 15 | NDM-1 | 2020 | RS | >256 | IncC | |
| 1009 | ICU | 15 | NDM-1 | 2020 | RTS | >256 | IncC | Yes |
| 1021 | PNE | 15 | NDM-1 | 2020 | RTS | >256 | IncC | Yes |
| 1027 | PNE | 15 | NDM-1 | 2020 | RTS | >256 | IncC | Yes |
| 9065 | ICU | 15 | NDM-1 | 2020 | RS | >256 | IncC | Yes |

ICU, intensive care unit; MED, medical clinic; HEM, hematology ward; SU, surgical unit; BC, blood culture; UR, urine; RS, rectal swab; WS, wound swab; RTS, respiratory tract sample; AF, ascitic fluid; WGS, whole-genome sequencing.



 $\textbf{Figure 1}. \ \textbf{Distribution of carbapenemases and ST in 2019-2021}.$




Figure 2. Correlation between CZA consumption and CZA-resistant strains.

Conclusions

In a high KPC endemicity nosocomial setting, CZA-resistance seemed to be supported by the horizontal gene transfer of pKpQIL that was highly conserved apart for the different bla_{KPC} mutated genes isolated in the observation period. Drug consumption data evidenced an intensive use of CZA during the study period inducing a constant selective pressure and most probably facilitating the emergence of CZA-resistant strains.

References

- 1) Carattoli A, Arcari G, Bibbolino G, Sacco F, Tomolillo D, Di Lella FM, Trancassini M, Faino L, Venditti M, Antonelli G, Raponi G. Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates. Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0057421.
- 2) Sacco F, Raponi G, Oliva A, Bibbolino G, Mauro V, Di Lella FM, Volpicelli L, Antonelli G, Venditti M, Carattoli A, Arcari G. An outbreak sustained by ST15 Klebsiella pneumoniae carrying 16S rRNA methyltransferases and bla_{NDM}: evaluation of the global dissemination of these resistance determinants. Int J Antimicrob Agents. 2022 Aug;60(2):106615